Impact of American Urological Association risk category on outcomes of intravesical BCG vs gemcitabine/docetaxel in high-grade Ta non-muscle-invasive bladder cancer

Genitourinary Cancer

Gemcitabine versus Bacillus Calmette-Guerin for Intravesical Therapy in Treatment-Naïve Low-Grade Intermediate-Risk Non-Muscle Invasive Bladder Cancer

J Urol

Khene ZE, Bhanvadia R, Attia S, Ito W, Trevino I, Woldu SL, Margulis V, Lotan Y

doi: 10.1097/JU.0000000000004472

Genitourinary Cancer

Efficacy and Safety of Checkpoint Inhibitors Combined with Bacillus Calmette-Guérin (BCG) in BCG-naïve High-risk Non-muscle-invasive Bladder Cancer: Synthesis of Evidence from the ALBAN, CREST, and POTOMAC Trials

Eur Urol

Scilipoti P, Zaurito P, Longoni M, Colecchia M, Montorsi F, Salonia A, Mercinelli C, Maiorano B, Necchi A, Briganti A, Moschini M

doi: 10.1016/j.eururo.2025.12.022

Genitourinary Cancer

Long-term outcomes of a cascading salvage strategy for high-risk non-muscle-invasive bladder cancer

BJU Int

McElree IM, Steinberg RL, Hougen HY, Mott SL, Packiam VT, O'Donnell MA

doi: 10.1111/bju.70044

COMMENTED

Genitourinary Cancer

Twelve-Month Results From the CISTO Study Comparing Radical Cystectomy Versus Bladder-Sparing Therapy for Recurrent High-Grade Non-Muscle-Invasive Bladder Cancer

★ 1 Recommended and commented by Prof. Dr Richard Cathomas, Faculty Member

J Clin Oncol

Gore JL, Wolff EM, Nash MG, Comstock BA, Gilbert SM, Chang SS, Chisolm S, MacLean DB, Wright JL, Kates MR, Pohar KS, Guzzo TJ, Bivalacqua TJ, Nepple KG, Montgomery JS, Scarpato KR, Woldu SL, Master VA, Chen DYT, Mossanen M, Daneshmand S, O'Neil BB, Tyson MD, Westerman ME, Kamat AM, Mansour AM, Chamie K, Riggs SB, Kukreja JB, Modi PK, Garg T, Peyton CC, Nix JW, Dickstein R, Gadzinski AJ, Sankin A, Shore ND, Lane BR, Bassett JC, Patel S, Morris DS, Macleod LC, Lee EK, Ritch CR, Follmer KM, Lee JR, Kim SM, Kessler LG, Smith AB, CISTO Collaborative group

doi: 10.1200/JCO-25-01324

Genitourinary Cancer

Defining statistical cure in patients with T1 high-grade non-muscle-invasive bladder carcinoma treated with BCG immunotherapy

BJU Int

Subiela JD, de la Parra I, Taborda J, Medina AA, Pichler R, Krajewski W, Ojeda CM, Mardomingo AF, Durán PDO, Pérez EL, González-Padilla DA, Aumatell J, Mori K, Scilipoti P, Longoni M, de Angelis M, Caño-Velasco J, Puentedura AL, Pujol LP, Contieri R, Gallioli A, Tukiendorf A, D'Andrea D, Teoh JY, Afferi L, Del Giudice F, Marcq G, Albisinni S, Soria F, Mertens LS, Laukhtina E, Tully K, Mari A, Guerrero-Ramos F, Alvarez-Maestro M, Martín CC, Melendres FA, Buisan O, López-González JA, Dominguez-Escrig JL, Aranda J, Elena JLR, Basile G, Santos VGD, Moschini M, Pradere B, Acosta EA, Palacio FL, Puig AC, Gajate P, Saiz A, Gontero P, Revilla FJB, From Young Academic Urologist: Urothelial Carcinoma Working Group

doi: 10.1111/bju.16913

Genitourinary Cancer

A Systematic Review of Novel Intravesical Approaches for the Treatment of Patients with Non-muscle-invasive Bladder Cancer

Eur Urol

Ghodoussipour S, Bivalacqua T, Bryan RT, Li R, Mir MC, Palou J, Psutka SP, Sundi D, Tyson MD, Inman BA

doi: 10.1016/j.eururo.2025.02.010

Genitourinary Cancer

Long-term Outcomes and Prognostic Impact of Residual Cancer Burden After Intensified Neoadjuvant Therapy in High-risk Prostate Cancer

Eur Urol

Ravi P, Kwak L, Acosta AM, Rastogi S, Xie W, Abdelnaser A, Einstein DJ, Chang P, Wagner AA, McKay RR, Kibel AS, Taplin ME

doi: 10.1016/j.eururo.2025.01.015

Genitourinary Cancer

Active Surveillance Versus Intravesical Bacillus Calmette-Guérin for High-grade T1 Bladder Cancer with Negative Second Transurethral Resection: The Randomized Noninferiority Phase 3 JCOG1019 Trial

Eur Urol

Kitamura H, Tsukamoto T, Kakehi Y, Mizusawa J, Shibata T, Sasaki K, Tanikawa T, Hashine K, Fujimoto K, Masumori N, Kobayashi T, Habuchi T, Kimura T, Sugimoto M, Takahashi A, Adachi H, Matsui Y, Hatakeyama S, Ito A, Eto M, Nishiyama H, Urologic Oncology Study Group of the Japan Clinical Oncology Group

doi: 10.1016/j.eururo.2026.01.008

Genitourinary Cancer

The impact of treatment for muscle-invasive bladder cancer on health-related quality of life

BJU Int

Nuijens ST, van Hoogstraten LMC, Terpstra NB, Beeren I, Vrieling A, Wijnen EM, Meijer RP, Kiemeney LA, Witjes JA, Aben KKH

doi: 10.1111/bju.16736

Related content

Gemcitabine versus Bacillus Calmette-Guerin for Intravesical Therapy in Treatment-Naïve Low-Grade Intermediate-Risk Non-Muscle Invasive Bladder Cancer

Efficacy and Safety of Checkpoint Inhibitors Combined with Bacillus Calmette-Guérin (BCG) in BCG-naïve High-risk Non-muscle-invasive Bladder Cancer: Synthesis of Evidence from the ALBAN, CREST, and POTOMAC Trials

Long-term outcomes of a cascading salvage strategy for high-risk non-muscle-invasive bladder cancer

Twelve-Month Results From the CISTO Study Comparing Radical Cystectomy Versus Bladder-Sparing Therapy for Recurrent High-Grade Non-Muscle-Invasive Bladder Cancer

Defining statistical cure in patients with T1 high-grade non-muscle-invasive bladder carcinoma treated with BCG immunotherapy

A Systematic Review of Novel Intravesical Approaches for the Treatment of Patients with Non-muscle-invasive Bladder Cancer

Long-term Outcomes and Prognostic Impact of Residual Cancer Burden After Intensified Neoadjuvant Therapy in High-risk Prostate Cancer

Active Surveillance Versus Intravesical Bacillus Calmette-Guérin for High-grade T1 Bladder Cancer with Negative Second Transurethral Resection: The Randomized Noninferiority Phase 3 JCOG1019 Trial

The impact of treatment for muscle-invasive bladder cancer on health-related quality of life